
# TB/HIV in the South-East Asia Region

From Mekong to Bali:
The scale up of TB/HIV collaborative activities in the Asia Pacific


August 8-9, 2009 Bali, Indonesia

### **Situation**


### **Estimated TB Incidence Rates**



# HIV Prevalence in the South-East Asia Region: 2008



## HIV prevalence stable/decreasing in most countries...




Source: The above adult HIV prevalence curves generated by Spectrum, Asia Epidemic model, are based on national surveillance data reported by Ministry of Health, SEAR countries

### but increasing in others.

Rapid increase in reported AIDS cases, Indonesia

3500 | 3000 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 25

Steady increase in HIV prevalence among injecting drug users. Bangladesh



Source: National AIDS Programme, Ministry of Health, Indonesia, 2006 Source: National AIDS Programme, Ministry of Health, Bangladesh, 2006


Indonesia has the fastest growing HIV epidemic in Asia

## HIV seroprevalence among TB cases

Country	Estimated HIV seroprevalence among incident TB cases	Country	Estimated HIV seroprevalence among incident TB cases
Bangladesh	< 0.05 %	Myanmar	10.9%
Bhutan	Not available	Nepal	2.4%
DPR Korea	Not applicable	Sri Lanka	0.2%
India	~4- 5%	Thailand	13-24%
Indonesia	2% -15% (Papua)	Timor-Leste	<100 cases of HIV reported/yr
Maldives	<5 cases of HIV reported/yr		

Source: Tuberculosis Control in the South-East Asia Region, WHO/SEARO, New Delhi, March 2009


## PLHIV: Categorization by Districts: India




- Districts with HIV
   prevalence among ANC
   attendees >1% at any site
   in past 3 years
- Districts with HIV prevalence among ANC <1% and > 5% among HRGs in past 3 years
- Districts with HIV prevalence among ANC <1% and < 5% among HRGs in past 3 years

Source: National AIDS Control Organization, MoH and FW, India


## **Estimates for PLHIV by district: Indonesia**



# Age and sex distribution: TB/HIV co-infected patients: Myanmar (2006-2008)



## Average age by sex of TB/HIV patients in Indonesia by HIV prevalence in provinces



## **Progress**

## WHO Policy on TB/HIV

#### A. Establish the mechanisms for collaboration

- A.1. Set up a coordinating body for TB/HIV activities effective at all levels
- A.2. Conduct surveillance of HIV prevalence among tuberculosis patients
- A.3. Carry out joint TB/HIV planning
- A.4. Conduct monitoring and evaluation

#### B. Decrease the burden of tuberculosis in people living with HIV/AIDS

- B.1. Establish intensified tuberculosis case-finding
- B.2. Introduce isoniazid preventive therapy
- B.3. Ensure tuberculosis infection control in health care and congregate settings

#### C. Decrease the burden of HIV in tuberculosis patients

- C.1. Provide HIV testing and counselling
- C.2. Introduce HIV prevention methods
- C.3. Introduce cotrimoxazole preventive therapy
- C.4. Ensure HIV/AIDS care and support
- C.5. Introduce antiretroviral therapy

## Strategy for TB-HIV in the SEA Region

+ the "4<sup>th</sup> I"

"Integrated case management"

3 l's

- + D. Systems strengthening
- Establish regular interaction
- Resource mobilization
- Capacity building
- Involve communities, NGOs

## **Progress at Country Level**

National Coordinating committees: 10/11 countries

Planning and Implementation:

Full package of TB/HIV interventions (barring IPT) now available to over a third of the population in the SEA Region

- Integrated nation-wide implementation: Thailand, India
  - "Intensified" package of interventions available to 400 million population in 11 states of India
- Scaling up in 3 countries: Indonesia, Myanmar and Nepal
- Case by case management: Maldives
- Preparations for collaborative interventions in 5 countries- Bangladesh, Bhutan, Sri Lanka, and Timor Leste

## Surveillance, Monitoring and Evaluation

### HIV in TB patients

- TB R and R formats include data on HIV among TB patients in 8 countries;
- routine reporting in India, Myanmar, Thailand; others to follow

#### TB in PLHIV

Much less reported data: better surveillance required in most settings


### Joint Monitoring and Evaluation

Needs to be systematically done in most settings

## The 3 "I's"


## **Intensified Case Finding**

# Intensified Case Finding – Screening for TB at ICTCs India, 2005-2008




Source: Monthly reports from ICTCs collated and reported by respective State AIDS Control Societies

# TB Cases Detected through ICF: India 2005–2008



Source: Monthly reports from ICTCs collated and reported by respective State AIDS Control Societies


## Intensified TB finding among newly detected PLHIV in Thailand, 2006-8




Source: Bureau of Tuberculosis Control, Dept of Disease Control, MopH Thailand, July 2009

### And vice versa

## TB patients Newly HIV Tested: India 2005-2008




## HIV testing among TB patients in Thailand, 2006-8.




Source: Bureau of Tuberculosis Control, Dept of Disease Control, MopH Thailand, July 2009

## **Case Management**

## TB-HIV patients receiving ART during TB treatment: Thailand



## TB-HIV patients receiving CPT during TB treatment; Thailand



## CD4 counts among TB/HIV Patients: Thailand

Cohort	No. HIV- Infected TB Patients	Died Before CD4 Test	Had CD4 Test	CD4 Count (cells / mm <sup>3</sup> )		
		Performed	Performed	<100	101-250	>250
2 & 3/	201	24%	50%	68%	19%	13%
2003	201	(48)	(101)	(69)	(19)	(13)
2004	349	9.2%	76%	69%	24%	7%
2004		(32)	(266)	(182)	(65)	(19)
2005	346	4%	69%	70%	19%	11%
2003	340	(14)	(237)	(165)	(45)	(27)
2006	341	5%	55%	69%	21%	10%
	341	(17)	(187)	(129)	(40)	(18)
2007	234	5%	77%	59%	22%	19%
	234	(12)	(181)	(106)	(40)	(35)

Source: ODPC 7, Ubon Rachatani, Thailand

# Treatment outcomes: New smear positive TB patients: Thailand, 2007

	Success	Fail	Died	Default	ТО
Total NM+	81.3%	1.7%	8.6%	4.9%	1.6%
TB (HIV+)	72.5%	2%	23.7%	6.2%	2.8%
TB (HIV-, unknown)	82.3%	1.7%	6.8%	4.8%	1.5%

## Linking HIV-Infected TB Patients to Cotrimoxazole Prophylaxis and Antiretroviral Treatment in India

Neeraj Raizada<sup>1</sup>, Lakbir Singh Chauhan<sup>2</sup>, B. Sai Babu<sup>3</sup>, Rahul Thakur<sup>4</sup>, Ajay Khera<sup>5</sup>, D. Fraser Wares<sup>4</sup>, Suvanand Sahu<sup>4</sup>, D. Bachani<sup>5</sup>, B. B. Rewari<sup>5</sup>, Puneet K. Dewan<sup>6</sup>\*

"Among HIV-infected TB patients in India death was common despite the availability of free co-trimoxazole locally and ART from referral centres. Death was strongly associated with the absence of ART during TB treatment. To minimize death, programmes should promote high levels of ART uptake and closely monitor progress in implementation."

ART to HIV-infer culosis in three districts in Andhra Pradesh, India, and evaluated factors associated with Methods and ectively abstracted data for all HIV-infected tuberculosis patients diagnosed from March 2007 throug ng standard treatment outcome definitions. 734 HIV-infected tuberculosis patients were males and 569 (80%) were between the ages of 24-44 years. 710 (97%) initiated CPT, and 351 identified; 4 (50%) colle of their monthly cotrimoxazole pouches provided throughout TB treatment. Access to ART was document (51%) patients. Overall 130 (17%) patients died during TB treatment. Patients receiving ART were less √usted hazard ratio [HR] 0.4, 95% confidence interval [CI] 0.3–0.6), while males and those with pulmonary TB likely to g nkely to die (HR 1.7, 95% CI 1.1–2.7, and HR 1.9, 95% CI 1.1–3.2 respectively). were me

Conclusions: Among HIV-infected TB patients in India death was common despite the availability of free cotrimoxazole locally and ART from referral centres. Death was strongly associated with the absence of ART during TB treatment. To minimize death, programmes should promote high levels of ART uptake and closely monitor progress in implementation.

Citation: Raizada N, Chauhan LS, Babu BS, Thakur R, Khera A, et al. (2009) Linking HIV-Infected TB Patients to Cotrimoxazole Prophylaxis and Antiretroviral Treatment in India. PLoS ONE 4(6): e5999. doi:10.1371/journal.pone.0005999

## Summarizing

Most HIV-TB patients are young, males, and do not know their HIV status when diagnosed for TB. 80% of those tested have CD4 counts below 250/cm—less than a fifth receive ART (reported) and nearly a quarter die....

### Infection Control

- Infection control measures included in national plans: Bhutan India, Indonesia, Myanmar, Nepal and Thailand
- Introduction of appropriate measures a slow process

#### Focus on building capacity--

- Bi-regional workshop on air-borne infection with CDC, MOH
   Thailand and CSR units of SEARO and WPRO held in August 2008
- Training materials on Airborne infection control developed
- In-country technical assistance, national workshops
- Regional workshop on infection control to prevent TB transmission in health facilities – September 2009

## **Airborne Infection Control (IC)**



Administrative, environmental controls,

Triaging...

### **IPT**

### Not policy in any country

Being piloted in Myanmar and Thailand Commonly heard concerns:

- It is difficult to rule out active TB; so we may end up giving monotherapy
- INH resistance is high; IPT could further magnify INH resistance.
- Managing adherence to IPT is too complicated and would be costly
- Not so effective—and IPT efficacy wanes with time

## The 4th "I": Integrated Case Management

### Principles:

- TB and HIV programmes benefit from close coordination and integration at service delivery level
- Patients benefit from a single source care for OI management, DOTS, CPT, and ART
- Programme efficiencies: Training, monitoring and evaluation
- The "Integrated Management of Adult Illness" (IMAI) training package for health staff is an option to move towards this goal

### Caveat:

Decentralized HIV services are critical to achieving integration

### "D" Strengthening systems...jointly

- Establishing regular interaction
- Resource mobilization
- Capacity building
- Involving communities and NGOs

### Issues

# Addressing TB/HIV: Fundamental challenge: Service delivery mismatch

Number of Health Institutions						
COUNTRY	TB Rx	TB Dx	HIV testing	ART	% with TB Tx and ART (assuming overlap; Ideal:100%)	Ratio TB Dx : VCT (Ideal : 1)
BANGLADESH	954	954	23	2	0.2%	41.48
BHUTAN	30	30	7	1	3.3%	4.29
DPR KOREA	285	285	34	0		8.38
INDIA	300000	12500	4889	211	<0.01%	2.74
INDONESIA	8000	4855	482	148	1.9%	10.07
MALDIVES	203	35	22	1	0.5%	1.59
MYANMAR	329	324	199	53	16.1%	1.62
NEPAL	4129	429	136	23	0.6%	3.15
SRI LANKA	26	26	26	5	19.2%	1
TIMOR LESTE	74	18	9	2	2.7%	2
THAILAND	847	1023	1014	1014	83.5%	1.01

## Addressing TB/HIV: Programmatic issues

- Systems for cross-referral, linkages between services:
- Approaches adopted to provide services, level of health facilities, involvement of other providers and communities (much to learn from each other)
- Health systems constraints
  - **Diagnostics and drugs:** availability HIV test kits, TB cultures, X-rays; difficult in practice to apply recommended algorithms
  - Personnel: Not enough trained, skilled and motivated personnel for counseling—fear among Health Workers, stigmatization of patients
- Infection control measures only now becoming a focus

## Addressing TB/HIV: Other challenges

- Confidentiality??
- Contact tracing in the face of strong social stigma?
- Capacity to look for MDR??
- Continuum of care regular repeat screening for TB?

### **TB/HIV**: Summary

- Wide variations in HIV prevalence, dynamic patterns across the Region, and within individual countries
- Substantial progress towards integration of TB/HIV activities into both programmes
- Less than 1/5<sup>th</sup> of PLHIV with active TB were reported in 2008 to have received ART
- Further decentralization of HIV counseling, care and treatment centres will help accelerate integration of TB/HIV services (4 "I's" at every HIV service deliver point)

# TB/HIV: The interim Goals in the SEA Region

### To achieve by 2015:

 Equitable access to the full package of interventions for TB/HIV "under one roof" to all population groups in the Region, through integration of service delivery by both programmes and further decentralization

### and as a result,

 Reduction in mortality rates among HIV-TB coaffected individuals to under 5%

## With many thanks to

National programme managers and staff of the 11 countries of the WHO South-East Asia Region

and

Staff from WHO HQ, SEARO and Country offices

who helped with the data and graphs used in this presentation